title: Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.
abstract: OBJECTIVE
  This study is aimed at analyzing the survival rates and prognostic factors of stage IV colorectal cancer patients from 3 European cohorts undergoing combination chemotherapy with bevacizumab.
  
  
  METHODS
  Progression free-survival (PFS) and overall survival (OS) were analyzed in 172 patients using the Kaplan-Meier method and uni- and multivariable Cox proportional hazards regression models.
  
  
  RESULTS
  The median PFS was 9.7 and the median OS 27.4 months. Patients treated at centers in Germany (n = 97), Ireland (n = 32), and The Netherlands (n = 43) showed a median PFS of 9.9, 9.2, and 9.7 months, OS of 34.0, 20.5, and 25.1 months, respectively. Patients >65 years had a significantly shorter PFS (9.5 vs. 9.8 months) but not OS (27.4 vs. 27.5 months) than younger patients. High tumor grade (G3/4) was associated with a shorter PFS, T4 classification with both shorter PFS and OS. Fluoropyrimidine (FP) chemotherapy backbones (doublets and single) had comparable outcomes, while patients not receiving FP backbones had a shorter PFS. In multivariable analysis, age and non-FP backbone were associated with inferior PFS, T4 classification and therapy line >2nd were significantly associated with poor PFS and OS.
  
  
  CONCLUSIONS
  The observed survival rates confirm previous studies and demonstrate reproducible benefits of combination bevacizumab regimens. Classification T4, non-FP chemotherapy backbone, and age >65 were associated with inferior outcome.
authors.affiliation: Department of Medicine II, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
authors.forename: Johannes
authors.initials: J
authors.lastname: Betge
authors.forename: Ana
authors.initials: A
authors.lastname: Barat
authors.forename: Verena
authors.initials: V
authors.lastname: Murphy
authors.forename: Thomas
authors.initials: T
authors.lastname: Hielscher
authors.forename: Nicole C
authors.initials: NC
authors.lastname: Van Grieken
authors.forename: Sebastian
authors.initials: S
authors.lastname: Belle
authors.forename: Tianzuo
authors.initials: T
authors.lastname: Zhan
authors.forename: Nicolai
authors.initials: N
authors.lastname: Härtel
authors.forename: Melanie
authors.initials: M
authors.lastname: Kripp
authors.forename: Orna
authors.initials: O
authors.lastname: Bacon
authors.forename: Martijn
authors.initials: M
authors.lastname: Cordes
authors.forename: Elaine W
authors.initials: EW
authors.lastname: Kay
authors.forename: Henk M W
authors.initials: HM
authors.lastname: Verheul
authors.forename: Maarten
authors.initials: M
authors.lastname: Neerincx
authors.forename: Bryan
authors.initials: B
authors.lastname: Hennessy
authors.forename: Ralf D
authors.initials: RD
authors.lastname: Hofheinz
authors.forename: Timo
authors.initials: T
authors.lastname: Gaiser
authors.forename: Bauke
authors.initials: B
authors.lastname: Ylstra
authors.forename: Jochen H M
authors.initials: JH
authors.lastname: Prehn
authors.forename: Diether
authors.initials: D
authors.lastname: Lambrechts
authors.forename: Annette T
authors.initials: AT
authors.lastname: Byrne
authors.forename: Matthias P
authors.initials: MP
authors.lastname: Ebert
authors.forename: Nadine
authors.initials: N
authors.lastname: Schulte
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011743:Pyrimidines / Q000627:therapeutic use; D012189:Retrospective Studies; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D020533:Angiogenesis Inhibitors; D011743:Pyrimidines; D000068258:Bevacizumab; C029269:5-fluoropyrimidine